Company Overview More
Vallon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of prescription drugs for central nervous system disorders. The company develops abuse-deterrent amphetamine immediate-release, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder and narcolepsy. It also develops ADMIR, an abuse deterrent formulation of Ritalin. Vallon Pharmaceuticals, Inc. was incorporated in 2018 and is based in Philadelphia, Pennsylvania.
CEO: Baker, David C.
Market: NASDAQ
Futu Hot List
USHKCN
Trade HeatSearch HeatNews Heat
SymbolLatest Price% Chg

Loading...

VLON Vallon Pharmaceuticals

5.310-0.080-1.48%
Close 11/26 16:50 ET
5.150-0.16-3.01%
Post Mkt Price 11/26 16:59 ET
High
5.390
Open
4.700
Turnover
2.97M
Low
4.650
Prev.Close
5.390
Volume
592.10K
Market Cap
36.18M
P/E(TTM)
Loss
52Wk High
10.360
Shares
6.81M
P/E
Loss
52Wk Low
3.610
H Mkt Cap
16.97M
Bid-Ask Ratio
-75.00%
Historical High
10.360
H Shares
3.20M
Vol. Ratio
0.17
Historical Low
3.610
Dividend TTM
--
Div Yield TTM
--
P/B
4.15
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
18.52%
Amplitude
13.73%
Avg Price
5.012
Min Trading Unit
1
Float Market Cap
16.97M
Bid-Ask Ratio
-75.00%
Historical High
10.360
Float
3.20M
Vol. Ratio
0.17
Historical Low
3.610
Dividend TTM
--
P/B
4.15
Dividend LFY
--
Turnover Ratio
18.52%
Amplitude
13.73%
Avg Price
5.012
Min Trading Unit
1
Price Forecast

Loading...

News